397 Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Eloxx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.20 |
| 52 Week High | US$28.80 |
| 52 Week Low | US$3.20 |
| Beta | 2.06 |
| 1 Month Change | -17.66% |
| 3 Month Change | -76.37% |
| 1 Year Change | -87.62% |
| 3 Year Change | -98.57% |
| 5 Year Change | n/a |
| Change since IPO | -98.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 397 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3,420.7% | 2.3% | 1.4% |
| 1Y | -87.6% | -14.5% | 9.1% |
Return vs Industry: 397 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 397 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 397 volatility | |
|---|---|
| 397 Average Weekly Movement | 1,181.2% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 397's share price has been volatile over the past 3 months.
Volatility Over Time: 397's weekly volatility has increased from 581% to 1181% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 28 | Sumit Aggarwal | www.eloxxpharma.com |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology.
Eloxx Pharmaceuticals, Inc. Fundamentals Summary
| 397 fundamental statistics | |
|---|---|
| Market cap | €5.86m |
| Earnings (TTM) | -€39.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs 397 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 397 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$41.84m |
| Earnings | -US$41.84m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -19.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -494.1% |
How did 397 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/11 05:26 |
| End of Day Share Price | 2022/12/06 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eloxx Pharmaceuticals, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |
| Andrew Fein | H.C. Wainwright & Co. |